Zhou Q B, Yang S X, Cui W M, Wang F Q, Chang Y, Sun H F, Yuan W T
Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Aug 25;26(8):763-767. doi: 10.3760/cma.j.cn441530-20230508-00154.
To investigate the feasibility and safety of a robotic surgical system (or laparoscopy) in combination with colonoscopy (combined) for the treatment of stage T1N0M0 colorectal cancer. This was a descriptive case series. Indications for combined dual-scope surgery in this study were as follows: (1) preoperative colonoscopic examination of lesions in the middle and upper rectum and colon with pathologically confirmed high-grade intraepithelial neoplasia, intramucosal adenocarcinoma, or adenocarcinoma; (2) no distant or local lymph node metastases; and (3) endoscopic ultrasound and magnetic resonance imaging evidence of tumor invasion of the mucosal or submucosal, but not the muscular, layer (i.e., T1). The clinical data of 13 patients with stage T1 colorectal cancer who had undergone dual-scope combined resection using a robotic surgery system or laparoscope-assisted combined colonoscopy surgery at the First Affiliated Hospital of Zhengzhou University from April to October 2022 were retrospectively collected, including 6 males and 7 females, with a median age of 59 (48~88) years old. The tumors were located in the upper and middle rectum in six patients, in the sigmoid colon in three, and in the ascending colon in four. The median maximum diameter of the tumors was 3.0 (1.8-5.0) cm. The surgery was performed by a robotic surgery system (or laparoscopy) with peritumoral D1 lymph node dissection at the first station in the tumor area. The tumors were resected under direct vision and the defects in the intestinal wall were using a robotic surgery system (or laparoscopy). A robotic surgery system was combined with colonoscopy in eight cases and laparoscopy combined with colonoscopy in the remaining five. Studied variables includes surgical and pathological features, postoperative factors, and outcomes. Surgery was successful in all 13 patients with no need for conversion to open surgery or intraoperative blood transfusion. The median operating time was 85 (60-120) minutes, median intraoperative bleeding 3 (2-5) mL, median number of lymph nodes harvested 3 (1-5), and the median circumferential resection margin 0.8 (0.5-1.0) cm. Postoperative pathological examination showed lymph node metastasis in one patient, who therefore underwent additional radical surgery. The median postoperative time to ambulation was 1 (1-2) days. The urinary catheters of all patients were removed 1 day after surgery and the median length of stay was 4 (3-5) days. No abdominal infection, anastomotic leakage or bleeding occurred in any of the study patients. The median follow-up time was 10 (6-12) months, during which no tumor recurrence or metastasis was found, and the quality of life was satisfactory. The combination of two minimally invasive platforms, a robotic surgery system (or laparoscopy) and colonoscopy, is safe and feasible for resection of stage T1 colorectal cancer and has a good short-term prognosis.
探讨机器人手术系统(或腹腔镜)联合结肠镜检查(联合手术)治疗T1N0M0期结直肠癌的可行性和安全性。这是一个描述性病例系列研究。本研究中联合双镜手术的指征如下:(1)术前结肠镜检查发现中高位直肠和结肠病变,病理确诊为高级别上皮内瘤变、黏膜内腺癌或腺癌;(2)无远处或局部淋巴结转移;(3)内镜超声和磁共振成像显示肿瘤侵犯黏膜或黏膜下层,但未侵犯肌层(即T1期)。回顾性收集了2022年4月至10月在郑州大学第一附属医院接受机器人手术系统或腹腔镜辅助联合结肠镜手术的13例T1期结直肠癌患者的临床资料,其中男性6例,女性7例,中位年龄59(4888)岁。肿瘤位于直肠中高位6例,乙状结肠3例,升结肠4例。肿瘤最大直径中位值为3.0(1.85.0)cm。手术采用机器人手术系统(或腹腔镜)在肿瘤区域进行第一站肿瘤周围D1淋巴结清扫。在直视下切除肿瘤,并使用机器人手术系统(或腹腔镜)处理肠壁缺损。8例采用机器人手术系统联合结肠镜检查,其余5例采用腹腔镜联合结肠镜检查。研究变量包括手术和病理特征、术后因素及结果。1,3例患者手术均成功,无需转为开放手术或术中输血。中位手术时间为85(60120)分钟,中位术中出血量3(25)mL,中位淋巴结清扫数3(15)个,中位环周切缘0.8(0.51.0)cm。术后病理检查发现1例患者有淋巴结转移,因此接受了额外的根治性手术。术后中位下床活动时间为1(12)天。所有患者术后1天拔除尿管,中位住院时间为4(35)天。研究患者均未发生腹腔感染、吻合口漏或出血。中位随访时间为10(6~12)个月,在此期间未发现肿瘤复发或转移,生活质量良好。机器人手术系统(或腹腔镜)与结肠镜检查这两种微创平台联合用于T1期结直肠癌切除是安全可行的,且短期预后良好。